Cagrilintide More Biotechnology Mazdutide and Tirzepatide: How These Dual Pathway Weight Loss Drugs Really Compare Peptides Unleashed In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond ScienceDirect Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed